GlassScriptPhysician profile
Christopher David Weaver
NPI 1407116494
$3,373.62
in general payments reported to CMS, 2019-2025
27 companies · $852 in 2025
The $852 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $473 · 2020: $181 · 2021: $360 · 2022: $797 · 2023: $344 · 2024: $366 · 2025: $852.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,562.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,562.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,043.71 | 2019-2025 | Clareon, Clareon Panoptix Pro, Argos |
| Notal Vision, INC. | $577.55 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $381.97 | 2021-2025 | Acthar |
| Abbvie INC. | $187.56 | 2022-2025 | Durysta |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $157.66 | 2019-2021 | |
| Allergan, INC. | $117.81 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $112.17 | 2019-2023 | |
| Tarsus Pharmaceuticals, INC. | $103.05 | 2024-2025 | Xdemvy |
| Dompe US, INC. | $89.17 | 2024-2025 | Oxervate |
| Horizon Therapeutics Plc | $73.44 | 2022-2023 | Tepezza |
| Kala Pharmaceuticals, INC. | $66.19 | 2020-2021 | |
| Ocular Therapeutix, INC. | $64.69 | 2019-2025 | Dextenza |
| Amgen INC. | $55.08 | 2024-2025 | Tepezza |
| Astellas Pharma US INC | $44.21 | 2025 | Izervay |
| New World Medical,INC. | $40.11 | 2020-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $39.12 | 2020-2022 | |
| Shire North American Group INC | $31.37 | 2019 | |
| Omeros Corporation | $30.76 | 2019-2020 | |
| Bausch & Lomb Americas INC. | $23.65 | 2022 | |
| Oyster Point Pharma, INC. | $21.82 | 2022 | |
| Harrow Eye, LLC | $20.36 | 2024 | Vevye |
| Thea Pharma INC. | $19.83 | 2025 | Iyuzeh |
| Sight Sciences, INC. | $17.71 | 2025 | Omni Surgical System, Sion Surgical Instrument |
| Aerie Pharmaceuticals, INC. | $16.23 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $14.76 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $12.83 | 2023 | Acuvue |
| Ivantis, INC | $10.81 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Weaver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.